Portal de Periódicos da CAPES

68 Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI

2015; Society of Nuclear Medicine and Molecular Imaging; Volume: 57; Issue: 2 Linguagem: Inglês

10.2967/jnumed.115.161018

1535-5667

Ingo Janssen, Clara C. Chen, David Taïeb, Nicholas J. Patronas, Corina Millo, Karen T. Adams, Joan Nambuba, Peter Herscovitch, Samira M. Sadowski, Antonio Tito Fojo, Inga Buchmann, Electron Kebebew, Karel Pacák,

Cancer, Hypoxia, and Metabolism

Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B , mutation-related metastatic pheochromocytomas/paragangliomas using 68 Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including 18 F-fluorohydroyphenylalanine ( 18 F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs. Methods: 68 Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent 18 F-FDOPA PET/CT, 18 F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing 18 F-fluorodopamine ( 18 F-FDA) PET/CT. 18 F-FDOPA PET/CT and CT/MRI served as the imaging comparators. Results: Thirty-eight lesions in 20 patients were detected, with 18 F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions ( P < 0.01). All 38 and an additional 7 lesions ( P = 0.016) were detected on 68 Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by 18 F-FDG PET/CT (24/38, P < 0.01) and 18 F-FDA PET/CT (10/34, P < 0.01). Conclusion: 68 Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that 68 Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.